Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors

Antiviral Research

Volumn 141, Issue , 2017, Pages 101-106

  Kumar, Vathan ^a   Shin, Jin Soo ^b   Shie, Jiun Jie ^c   Ku, Keun Bon ^b   Kim, Chonsaeng ^b   Go, Yun Young ^b   Huang, Kai Fa ^a   Kim, Meehyein ^b   Liang, Po Huang ^a,d  

^a INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c INSTITUTE OF CHEMISTRY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

3C like protease; Coronavirus; MERS CoV; Peptidomimetic inhibitor; Picornavirus; SARS CoV

Indexed keywords

ANTIVIRUS AGENT; PEPTIDOMIMETIC AGENT; PHENYLALANINE; VIRAL PROTEIN; PROTEINASE INHIBITOR;

ALPHACORONAVIRUS; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BETACORONAVIRUS; CONTROLLED STUDY; COVALENT BOND; DOWN REGULATION; DRUG IDENTIFICATION; DRUG SCREENING; EC50; ENTEROVIRUS; ENZYMATIC ASSAY; FELINE CORONAVIRUS; HUMAN; HUMAN CELL; IC50; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR DOCKING; NONHUMAN; PLAQUE ASSAY; PRIORITY JOURNAL; SARS CORONAVIRUS; SELECTIVITY INDEX; VIRUS PARTICLE; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; CAT; CHEMISTRY; CORONAVIRINAE; CORONAVIRUS INFECTION; DRUG DEVELOPMENT; DRUG EFFECTS; EVALUATION STUDY; ISOLATION AND PURIFICATION; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CATS; CORONAVIRUS; CORONAVIRUS INFECTIONS; DRUG DISCOVERY; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PEPTIDOMIMETICS; PROTEASE INHIBITORS; SARS VIRUS; VIRAL PROTEINS;

EID: 85013824590     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2017.02.007     Document Type: Article

References (39)

1. Akaji, K., Konno, H., Mitsui, H., Teruya, K., Shimamoto, Y., Hattori, Y., Ozaki, T., Kusunoki, M., Sanjoh, A., Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors. J. Med. Chem. 54 (2011), 7962–7973.
2. Akaji, K., Konno, H., Onozuka, M., Makino, A., Saito, H., Nosaka, K., Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant. Bioorg. Med. Chem. 16 (2008), 9400–9408.
3. Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J.R., Hilgenfeld, R., Coronavirus main proteinase (3CL(pro)) structure: basis for design of anti-SARS drugs. Science 300 (2003), 1763–1767.
4. Barnard, D.L., Kumaki, Y., Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. Future Virol. 6 (2011), 615–631.
5. Chan, J.F., Chan, K.H., Choi, G.K., To, K.K., Tse, H., Cai, J.P., Yeung, M.L., Cheng, V.C., Chen, H., Che, X.Y., Lau, S.K., Woo, P.C., Yuen, K.Y., Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J. Infect. Dis. 207 (2013), 1743–1752.
6. de Wilde, A.H., Raj, V.S., Oudshoorn, D., Bestebroer, T.M., van Nieuwkoop, S., Limpens, R.W.A.L., Posthuma, C.C., van der Meer, Y., Bárcena, M., Haagmans, B.L., Snijder, E.J., van den Hoogen, B.G., MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J. Gen. Virol. 94 (2013), 1749–1760.
7. Dyall, J., Coleman, C.M., Hart, B.J., Venkataraman, T., Holbrook, M.R., Kindrachuk, J., Johnson, R.F., Olinger, G.G. Jr., Jahrling, P.B., Laidlaw, M., Johansen, L.M., Lear-Rooney, C.M., Glass, P.J., Hensley, L.E., Frieman, M.B., Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58 (2014), 4885–4893.
8. Fan, K., Wei, P., Feng, Q., Chen, S., Huang, C., Ma, L., Lai, B., Pei, J., Liu, Y., Chen, J., Lai, L., Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J. Biol. Chem. 279 (2004), 1637–1642.
9. Ghosh, A.K., Xi, K., Ratia, K., Santarsiero, B.D., Fu, W., Harcourt, B.H., Rota, P.A., Baker, S.C., Johnson, M.E., Mesecar, A.D., Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J. Med. Chem. 48 (2005), 6767–6771.
10. Hilgenfeld, R., Peiris, M., From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antivir. Res. 100 (2013), 286–295.
11. Hsu, M.F., Kuo, C.J., Chang, K.T., Chang, H.C., Chou, C.C., Ko, T.P., Shr, H.L., Chang, G.G., Wang, A.H.J., Liang, P.H., Mechanism of the maturation process of SARS-CoV 3CL protease. J. Biol. Chem. 280 (2005), 31257–31266.
12. Ho, B.L., Cheng, S.C., Shi, L., Wang, T.Y., Ho, K.I., Chou, C.Y., Critical assessment of the important residues involved in the dimerization and catalysis of MERS coronavirus main protease. PLos One, 10, 2015, e0144865.
13. Jetsadawisut, W., Nutho, B., Meeprasert, A., Rungrotmongkol, T., Kungwan, N., Wolschann, P., Hannongbua, S., Susceptibility of inhibitors against 3C protease of coxsackievirus A16 and enterovirus A71 causing hand, foot and mouth disease: a molecular dynamics study. Biophys. Chem. 219 (2016), 9–16.
14. Kilianski, A., Baker, S.C., Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors. Antivir. Res. 101 (2014), 105–112.
15. Kim, Y., Shivanna, V., Narayanan, S., Prior, A.M., Weerasekara, S., Hua, D.H., Kankanamalage, A.C., Groutas, W.C., Chang, K.O., Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses. J. Virol. 89 (2015), 4942–4950.
16. Kumar, V., Jung, Y.S., Liang, P.H., Anti-SARS coronavirus agents: a patent review (2008-present). Expert Opin. Ther. Pat. 23 (2013), 1337–1348.
17. Kumar, V., Tan, K.P., Wang, Y.M., Lin, S.W., Liang, P.H., Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorg. Med. Chem. 24 (2016), 3035–3042.
18. Kuo, C.J., Liang, P.H., Characterization and inhibition of the main protease of severe acute respiratory syndrome coronavirus. ChemBioEng Rev. 2 (2015), 118–132.
19. Kuo, C.J., Chi, Y.H., Hsu, J.T.A., Liang, P.H., Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate. Biochem. Biophys. Res. Commun. 318 (2004), 862–867.
20. Kuo, C.J., Shie, J.J., Fang, J.M., Yen, G.R., Hsu, J.T.A., Liu, H.G., Tseng, S.N., Chang, S.C., Lee, C.Y., Shih, S.R., Liang, P.H., Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg. Med. Chem. 16 (2008), 7388–7398.
21. Lee, C.C., Kuo, C.J., Ko, T.P., Hsu, M.F., Tsui, Y.C., Chang, S.C., Yang, S., Chen, S.J., Chen, H.C., Hsu, M.C., Shih, S.R., Liang, P.H., Wang, A.H., Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds. J. Biol. Chem. 284 (2009), 7646–7655.
22. Matthews, D.A., Dragovich, P.S., Webber, S.E., Fuhrman, S.A., Patick, A.K., Zalman, L.S., Hendrickson, T.F., Love, R.A., Prins, T.J., Marakovits, J.T., Zhou, R., Tikhe, J., Ford, C.E., Meador, J.W., Ferre, R.A., Brown, E.L., Binford, S.L., Brothers, M.A., DeLisle, D.M., Worland, S.T., Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U.S.A. 96 (1999), 11000–11007.
23. Needle, D., Lountos, G.T., Waugh, D.S., Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity. Acta Cryst. D71 (2015), 1102–1111.
24. Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., Jung, S.H., An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J. Med. Chem. 59 (2016), 6595–6628.
25. Ramajayam, R., Tan, K.P., Liang, P.H., Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Biochem. Soc. Trans. 39 (2011), 1371–1375.
26. Rota, P.A., Oberste, M.S., Monroe, S.S., Nix, W.A., Campagnoli, R., Icenogle, J.P., Penaranda, S., Bankamp, B., Maher, K., Chen, M.H., Tong, S., Tamin, A., Lowe, L., Frace, M., DeRisi, J.L., Chen, Q., Wang, D., Erdman, D.D., Peret, T.C., Burns, C., Ksiazek, T.G., Rollin, P.E., Sanchez, A., Liffick, S., Holloway, B., Limor, J., McCaustland, K., Olsen-Rasmussen, M., Fouchier, R., Gunther, S., Osterhaus, A.D., Drosten, C., Pallansch, M.A., Anderson, L.J., Bellini, W.J., Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 (2003), 1394–1399.
27. Shie, J.J., Fang, J.M., Kuo, T.H., Kuo, C.J., Liang, P.H., Huang, H.J., Wu, Y.T., Jan, J.T., Cheng, Y.S., Wong, C.H., Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic α,β-unsaturated esters. Bioorg. Med. Chem. 13 (2005), 5240–5252.
28. St John, S.E., Tomar, S., Stauffer, S.R., Mesecar, A.D., Targeting zoonotic viruses: structure-based inhibition of the 3C-like protease from bat coronavirus HKU4-The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS). Bioorg. Med. Chem. 23 (2015), 6036–6048.
29. Thanigaimalai, P., Konno, S., Yamamoto, T., Koiwai, Y., Taguchi, A., Takayama, K., Yakushiji, F., Akaji, K., Chen, S.E., Naser-Tavakolian, A., Schon, A., Freire, E., Hayashi, Y., Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies. Eur. J. Med. Chem. 68 (2013), 372–384.
30. Thiel, V., Herold, J., Schelle, B., Siddell, S.G., Viral replicase gene products suffice for coronavirus discontinuous transcription. J. Virol. 75 (2001), 6676–6681.
31. Thiel, V., Ivanov, K.A., Putics, A., Hertzig, T., Schelle, B., Bayer, S., Weissbrich, B., Snijder, E.J., Rabenau, H., Doerr, H.W., Gorbalenya, A.E., Ziebuhr, J., Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 84 (2003), 2305–2315.
32. Tomar, S., Johnston, M.L., St John, S.E., Osswald, H.L., Nyalapatla, P.R., Paul, L.N., Ghosh, A.K., Denison, M.R., Mesecar, A.D., Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro): implications for nsp5 regulation and the development of antivirals. J. Biol. Chem. 290 (2015), 19403–19422.
33. Tong, T.R., Therapies for coronaviruses. Part 2: inhibitors of intracellular life cycle. Expert Opin. Ther. Pat. 19 (2009), 415–431.
34. Tyrrell, D.A., Bynoe, M.L., Cultivation of a novel type of common-cold virus in organ cultures. Br. Med. J. 1 (1965), 1467–1470.
35. Webber, S.E., Okano, K., Little, T.L., Reich, S.H., Xin, Y., Fuhrman, S.A., Matthews, D.A., Love, R.A., Hendrickson, T.F., Patick, A.K., Meador, J.W. 3rd, Ferre, R.A., Brown, E.L., Ford, C.E., Binford, S.L., Worland, S.T., Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. J. Med. Chem. 42 (1998), 2786–2805.
36. Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., Gao, G.F., Anand, K., Bartlam, M., Hilgenfeld, R., Rao, Z., The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 13190–13195.
37. Yang, S., Chen, S.J., Hsu, M.F., Wu, J.D., Tseng, C.T., Liu, Y.F., Chen, H.C., Kuo, C.W., Wu, C.S., Chang, L.W., Chen, W.C., Liao, S.Y., Chang, T.Y., Hung, H.H., Shr, H.L., Liu, C.Y., Huang, Y.A., Chang, L.Y., Hsu, J.C., Peters, C.J., Wang, A.H., Hsu, M.C., Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J. Med. Chem. 49 (2006), 4971–4980.
38. Zhao, Q., Weber, E., Yang, H., Recent developments on coronavirus main protease/3C like protease inhibitors. Recent Pat. Antiinfect. Drug Discov. 8 (2013), 150–156.
39. Zhu, L., George, S., Schmidt, M.F., Al-Gharabli, S.I., Rademann, J., Hilgenfeld, R., Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antivir. Res. 92 (2011), 204–212.